Amy J. Davidoff
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Amy J. Davidoff has a total of 212 co-authors. Here are the top co-authors by number of shared publications:
- Scott F. Huntington
Yale University, New Haven, CT
13 shared publications - Amer Methqal Zeidan
Hematology Section, Department of Internal Medicine, Yale School of Medicine, New Haven, CT
11 shared publications Rong Wang
Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University School of Medicine, New Haven, USA
10 shared publications- Nikolai A. Podoltsev
YALE UNIVERSITY SCHOOL OF MEDICINE, NEW HAVEN, CONNECTICUT, United States
9 shared publications - Roxanne E. Jensen
Outcomes Research Branch, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD
9 shared publications Steven D. Gore
Cancer Outcomes, Public Policy, and Effectiveness Research Center and
9 shared publications
Latest Publications
- Open Access
- 29 January 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (3) , 661-664
Smoldering multiple myeloma in the United States: a population-based analysis
- 29 January 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (3) , 661-664
Open AccessSmoldering multiple myeloma in the United States: a population-based analysis
- Open Access
- 13 January 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (4) , 923-925
Trends in Smoldering Myeloma Incidence in the United States From Cancer Registries, 2012–2022
- 13 January 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (4) , 923-925
Open AccessTrends in Smoldering Myeloma Incidence in the United States From Cancer Registries, 2012–2022
Contemporary neighborhood redlining and racial mortgage lending bias and disparities in prostate cancer survival
Background: Mortgage lending bias is a critical driver of residential segregation, and may contribute to disparities in cancer survival. This study investigated the association between contemporary redlining and racial lending bias and prostate cancer survival.Methods: This cohort study used a Surveillance, Epidemiology, and End Results–Medicare database that included 34,163 Black and White men diagnosed with prostate cancer between 2010 and 2013. Home Mortgage Disclosure Act data were used to calculate the census‐tract redlining index (the systematic denial of mortgages based on property location) and racial lending bias index (the systematic denial of a mortgage application for a Black applicant compared with a White applicant in the local area). Both indices were assessed continuously and categorically (low, moderate, or high). Multivariable‐adjusted Cox models were used to estimate hazard ratios (HRs) for prostate cancer–specific and all‐cause mortality.Results: Overall, as the redlining index increased, men experienced poorer prostate cancer survival. Compared to men residing in low‐redlined neighborhoods, those in high‐redlined neighborhoods had an increased risk of prostate cancer–specific mortality (HR, 1.21; 95% confidence interval [CI], 1.03–1.42) and all‐cause mortality (HR, 1.25; 95% CI, 1.17–1.34). Similar results were observed for redlining in a race‐stratified analysis among Black and White men. Among White men, compared with those residing in low racial lending bias neighborhoods, those in high racial lending bias neighborhoods had an increased all‐cause mortality risk (HR, 1.11; 95% CI, 1.03–1.21).Conclusions: Contemporary redlining was associated with poorer prostate cancer survival in the overall population. However, an association between racial lending bias and elevated mortality was only observed among White men. Findings suggest that mortgage lending discrimination may contribute to disparities in prostate cancer survival.
Contemporary neighborhood redlining and racial mortgage lending bias and disparities in prostate cancer survival
Background: Mortgage lending bias is a critical driver of residential segregation, and may contribute to disparities in cancer survival. This study investigated the association between contemporary redlining and racial lending bias and prostate cancer survival.Methods: This cohort study used a Surveillance, Epidemiology, and End Results–Medicare database that included 34,163 Black and White men diagnosed with prostate cancer between 2010 and 2013. Home Mortgage Disclosure Act data were used to calculate the census‐tract redlining index (the systematic denial of mortgages based on property location) and racial lending bias index (the systematic denial of a mortgage application for a Black applicant compared with a White applicant in the local area). Both indices were assessed continuously and categorically (low, moderate, or high). Multivariable‐adjusted Cox models were used to estimate hazard ratios (HRs) for prostate cancer–specific and all‐cause mortality.Results: Overall, as the redlining index increased, men experienced poorer prostate cancer survival. Compared to men residing in low‐redlined neighborhoods, those in high‐redlined neighborhoods had an increased risk of prostate cancer–specific mortality (HR, 1.21; 95% confidence interval [CI], 1.03–1.42) and all‐cause mortality (HR, 1.25; 95% CI, 1.17–1.34). Similar results were observed for redlining in a race‐stratified analysis among Black and White men. Among White men, compared with those residing in low racial lending bias neighborhoods, those in high racial lending bias neighborhoods had an increased all‐cause mortality risk (HR, 1.11; 95% CI, 1.03–1.21).Conclusions: Contemporary redlining was associated with poorer prostate cancer survival in the overall population. However, an association between racial lending bias and elevated mortality was only observed among White men. Findings suggest that mortgage lending discrimination may contribute to disparities in prostate cancer survival.
- Open Access
- 28 August 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (16) , e70131
Evolving patterns in systemic treatment utilization and survival among older patients with advanced cutaneous melanoma
Introduction: In the last decade, melanoma treatment has improved significantly. However, data on population‐level treatment utilization and survival trends among older patients is limited. This study aimed to analyze trends in systemic anticancer therapy (Rx), including the uptake of immune checkpoint inhibitors (ICIs), in conjunction with trends in cause‐specific survival among older patients (66+) diagnosed with advanced melanoma (2008–2019).Methods: We used the Surveillance, Epidemiology, and End Results (SEER)‐Medicare Condensed Resource to assess any Rx utilization among patients first diagnosed with advanced melanoma in 2008–2010, 2011–2014, and 2015–2019, stratified by stage, and type of first‐line Rx among patients receiving Rx. The SEER dataset was used to evaluate trends in cause‐specific survival by year of diagnosis.Results: Rx utilization (any type) almost doubled, from 28.6% (2008–2010) to 55.4% (2015–2019) for stage 3 melanoma, and from 35.5% to 68.0% for stage 4 melanoma. In 2008–2010, the standard first‐line treatment was cytokines/cytotoxic chemotherapy/other. By 2015–2019, only 5.1% (stage 3) and <3.6% (stage 4) of patients receiving Rx received these agents, as ICIs emerged as the dominant treatment. Both 1‐year and 5‐year cause‐specific survival significantly improved since 2010 for stage 4 and since 2013 for stage 3.Conclusions: This study shows a significant rise in Rx utilization and a rapid transition from cytokines/cytotoxic chemotherapy to ICIs, reflecting a rapid uptake of highly effective treatment in a previously challenging disease with limited options before 2011. The documented survival improvement aligns with the adoption of these novel treatments, underscoring their significant impact on real‐world patient outcomes.
- 28 August 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (16) , e70131
Open AccessEvolving patterns in systemic treatment utilization and survival among older patients with advanced cutaneous melanoma
Introduction: In the last decade, melanoma treatment has improved significantly. However, data on population‐level treatment utilization and survival trends among older patients is limited. This study aimed to analyze trends in systemic anticancer therapy (Rx), including the uptake of immune checkpoint inhibitors (ICIs), in conjunction with trends in cause‐specific survival among older patients (66+) diagnosed with advanced melanoma (2008–2019).Methods: We used the Surveillance, Epidemiology, and End Results (SEER)‐Medicare Condensed Resource to assess any Rx utilization among patients first diagnosed with advanced melanoma in 2008–2010, 2011–2014, and 2015–2019, stratified by stage, and type of first‐line Rx among patients receiving Rx. The SEER dataset was used to evaluate trends in cause‐specific survival by year of diagnosis.Results: Rx utilization (any type) almost doubled, from 28.6% (2008–2010) to 55.4% (2015–2019) for stage 3 melanoma, and from 35.5% to 68.0% for stage 4 melanoma. In 2008–2010, the standard first‐line treatment was cytokines/cytotoxic chemotherapy/other. By 2015–2019, only 5.1% (stage 3) and <3.6% (stage 4) of patients receiving Rx received these agents, as ICIs emerged as the dominant treatment. Both 1‐year and 5‐year cause‐specific survival significantly improved since 2010 for stage 4 and since 2013 for stage 3.Conclusions: This study shows a significant rise in Rx utilization and a rapid transition from cytokines/cytotoxic chemotherapy to ICIs, reflecting a rapid uptake of highly effective treatment in a previously challenging disease with limited options before 2011. The documented survival improvement aligns with the adoption of these novel treatments, underscoring their significant impact on real‐world patient outcomes.
- Open Access
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Do Contemporary Cancer Survivors Experience Better Quality of Life? Evaluating a Decade of SEER Medicare Health Outcomes Survey Data
Supplementary Table S1 lists the IC-O-3 site codes for the ten cancers analyzed in the manuscript.
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Do Contemporary Cancer Survivors Experience Better Quality of Life? Evaluating a Decade of SEER Medicare Health Outcomes Survey Data
Supplementary Table S1 lists the IC-O-3 site codes for the ten cancers analyzed in the manuscript.
- Open Access
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Data from Do Contemporary Cancer Survivors Experience Better Quality of Life? Evaluating a Decade of SEER Medicare Health Outcomes Survey Data
Background:A cancer diagnosis may have deleterious effects on health-related quality of life (HRQOL) as adults age. This study examined differences in HRQOL between cancer and matched noncancer Medicare beneficiaries over 65, within and across two time periods.Methods:We used novel matching methods on data from the Surveillance, Epidemiology and End Results (SEER)-Medicare Health Outcomes Survey (MHOS) data resource. We matched SEER-MHOS respondents with cancer from a recent period (2015–2019) to respondents with cancer from an earlier period (2008–2012). We then matched these two cohorts, without replacement, to contemporary cohorts without cancer diagnoses. We estimated Veteran's RAND 12-Item Short Form Survey Physical Component Summary (PCS) and Mental Component Summary (MCS) scores for all cohorts.Results:Our analysis found significantly higher mean MCS scores in the recent period for those with cancer relative to the recent noncancer control group. Breast and lung cancer presented positive and statistically significant trends. We found statistically insignificant differences in PCS scores between the two time periods. No cancer sites had different PCS scores over time compared with the comparison group.Conclusions:Mental health for those with cancer improved more between 2008 and 2019 than a matched noncancer comparison group. Physical health remained stable across time. These findings highlight the importance of including a matched noncancer group when evaluating HRQOL outcomes.Impact:SEER-MHOS respondents with cancer report stable PCS scores across 15 years of data and higher MCS scores relative to noncancer controls.
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Do Contemporary Cancer Survivors Experience Better Quality of Life? Evaluating a Decade of SEER Medicare Health Outcomes Survey Data
Background:A cancer diagnosis may have deleterious effects on health-related quality of life (HRQOL) as adults age. This study examined differences in HRQOL between cancer and matched noncancer Medicare beneficiaries over 65, within and across two time periods.Methods:We used novel matching methods on data from the Surveillance, Epidemiology and End Results (SEER)-Medicare Health Outcomes Survey (MHOS) data resource. We matched SEER-MHOS respondents with cancer from a recent period (2015–2019) to respondents with cancer from an earlier period (2008–2012). We then matched these two cohorts, without replacement, to contemporary cohorts without cancer diagnoses. We estimated Veteran's RAND 12-Item Short Form Survey Physical Component Summary (PCS) and Mental Component Summary (MCS) scores for all cohorts.Results:Our analysis found significantly higher mean MCS scores in the recent period for those with cancer relative to the recent noncancer control group. Breast and lung cancer presented positive and statistically significant trends. We found statistically insignificant differences in PCS scores between the two time periods. No cancer sites had different PCS scores over time compared with the comparison group.Conclusions:Mental health for those with cancer improved more between 2008 and 2019 than a matched noncancer comparison group. Physical health remained stable across time. These findings highlight the importance of including a matched noncancer group when evaluating HRQOL outcomes.Impact:SEER-MHOS respondents with cancer report stable PCS scores across 15 years of data and higher MCS scores relative to noncancer controls.
- Open Access
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Do Contemporary Cancer Survivors Experience Better Quality of Life? Evaluating a Decade of SEER Medicare Health Outcomes Survey Data
Supplementary Table S2 displays the complete pre-matching covariate balance statistics
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Do Contemporary Cancer Survivors Experience Better Quality of Life? Evaluating a Decade of SEER Medicare Health Outcomes Survey Data
Supplementary Table S2 displays the complete pre-matching covariate balance statistics
- Open Access
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Do Contemporary Cancer Survivors Experience Better Quality of Life? Evaluating a Decade of SEER Medicare Health Outcomes Survey Data
Supplementary Table S2 displays the complete pre-matching covariate balance statistics
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Do Contemporary Cancer Survivors Experience Better Quality of Life? Evaluating a Decade of SEER Medicare Health Outcomes Survey Data
Supplementary Table S2 displays the complete pre-matching covariate balance statistics
- Open Access
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Do Contemporary Cancer Survivors Experience Better Quality of Life? Evaluating a Decade of SEER Medicare Health Outcomes Survey Data
Supplementary Table S1 lists the IC-O-3 site codes for the ten cancers analyzed in the manuscript.
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Do Contemporary Cancer Survivors Experience Better Quality of Life? Evaluating a Decade of SEER Medicare Health Outcomes Survey Data
Supplementary Table S1 lists the IC-O-3 site codes for the ten cancers analyzed in the manuscript.
- Open Access
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Data from Do Contemporary Cancer Survivors Experience Better Quality of Life? Evaluating a Decade of SEER Medicare Health Outcomes Survey Data
Background:A cancer diagnosis may have deleterious effects on health-related quality of life (HRQOL) as adults age. This study examined differences in HRQOL between cancer and matched noncancer Medicare beneficiaries over 65, within and across two time periods.Methods:We used novel matching methods on data from the Surveillance, Epidemiology and End Results (SEER)-Medicare Health Outcomes Survey (MHOS) data resource. We matched SEER-MHOS respondents with cancer from a recent period (2015–2019) to respondents with cancer from an earlier period (2008–2012). We then matched these two cohorts, without replacement, to contemporary cohorts without cancer diagnoses. We estimated Veteran's RAND 12-Item Short Form Survey Physical Component Summary (PCS) and Mental Component Summary (MCS) scores for all cohorts.Results:Our analysis found significantly higher mean MCS scores in the recent period for those with cancer relative to the recent noncancer control group. Breast and lung cancer presented positive and statistically significant trends. We found statistically insignificant differences in PCS scores between the two time periods. No cancer sites had different PCS scores over time compared with the comparison group.Conclusions:Mental health for those with cancer improved more between 2008 and 2019 than a matched noncancer comparison group. Physical health remained stable across time. These findings highlight the importance of including a matched noncancer group when evaluating HRQOL outcomes.Impact:SEER-MHOS respondents with cancer report stable PCS scores across 15 years of data and higher MCS scores relative to noncancer controls.
- 3 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Do Contemporary Cancer Survivors Experience Better Quality of Life? Evaluating a Decade of SEER Medicare Health Outcomes Survey Data
Background:A cancer diagnosis may have deleterious effects on health-related quality of life (HRQOL) as adults age. This study examined differences in HRQOL between cancer and matched noncancer Medicare beneficiaries over 65, within and across two time periods.Methods:We used novel matching methods on data from the Surveillance, Epidemiology and End Results (SEER)-Medicare Health Outcomes Survey (MHOS) data resource. We matched SEER-MHOS respondents with cancer from a recent period (2015–2019) to respondents with cancer from an earlier period (2008–2012). We then matched these two cohorts, without replacement, to contemporary cohorts without cancer diagnoses. We estimated Veteran's RAND 12-Item Short Form Survey Physical Component Summary (PCS) and Mental Component Summary (MCS) scores for all cohorts.Results:Our analysis found significantly higher mean MCS scores in the recent period for those with cancer relative to the recent noncancer control group. Breast and lung cancer presented positive and statistically significant trends. We found statistically insignificant differences in PCS scores between the two time periods. No cancer sites had different PCS scores over time compared with the comparison group.Conclusions:Mental health for those with cancer improved more between 2008 and 2019 than a matched noncancer comparison group. Physical health remained stable across time. These findings highlight the importance of including a matched noncancer group when evaluating HRQOL outcomes.Impact:SEER-MHOS respondents with cancer report stable PCS scores across 15 years of data and higher MCS scores relative to noncancer controls.